Open Orphan Plc

Open Orphan Plc We have changed our name to hVIVO, Ticker: HVO. Follow hVIVO for company updates.

hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Today we officially change our name to HVIVO on London Stock Exchange AIM and Euronext📣Find all the latest news & invest...
26/10/2022

Today we officially change our name to HVIVO on London Stock Exchange AIM and Euronext📣

Find all the latest news & investor information here:
www.hvivo.com

👉Don’t forget to start following .
📈 Our new ticker is

Following this mornings announcement on Stephen Pinkerton's appointment as & Executive Director for the group, he caug...
18/10/2022

Following this mornings announcement on Stephen Pinkerton's appointment as & Executive Director for the group, he caught up with Vox Markets to discuss his experience & how this change aligns with the company growth

Tune in👂

https://www.voxmarkets.co.uk/articles/stephen-pinkerton-new-cfo-of-open-orphan-discusses-his-experience-and-expectations--869ae7b

Stephen Pinkerton new CFO of Open Orphan discusses his experience and positive expectations for the company with a record contracted order book, which has increased nearly threefold to c. £70m as at 30 June 2022.

Great day yesterday at the World Vaccine Congress 2022 event, held in the beautiful city of . Our presented "Utilis...
13/10/2022

Great day yesterday at the World Vaccine Congress 2022 event, held in the beautiful city of .

Our presented "Utilising human challenge models to advance vaccine development". We hope our industry colleagues enjoyed the presentation & we look forward to the remainder of the event.

We are located at stand: 67

As part of our company name change to hVIVO, our social media will be moving across to the HVIVO socials. Make sure you ...
10/10/2022

As part of our company name change to hVIVO, our social media will be moving across to the HVIVO socials. Make sure you follow to keep up to date with company newsflow.

See you there! The name change countdown is on...

Our ticker will also be changing to HVO

06/10/2022

We announced that we will be changing our name from Open Orphan Plc to on 26 Oct 2022. Our ticker will be changing from to .

Watch below to see reasons why we decided to make this strategic business decision...

Follow HVIVO to keep up to date!

Our new investors section will be going live alongside our name change launch which is expected to take place on 26 Octo...
03/10/2022

Our new investors section will be going live alongside our name change launch which is expected to take place on 26 October 2022.

Stay tuned...👀 and don't forget to follow HVIVO for updates

Here 's Chris Rhodes & analyst Daniel Appiah discuss 's H1 results. They highlight increasing demand for challenge tria...
20/09/2022

Here 's Chris Rhodes & analyst Daniel Appiah discuss 's H1 results. They highlight increasing demand for challenge trials & growing contract order book, which stands at over £80mln — almost 3X the value during the same period FY2021

Proactive analyst, Daniel Appiah, discusses with Chris Rhodes his latest assessment of Open Orphan. The company now has challenge studies running in 10 diffe...

The Proactive note published today following the publication of our H1 results.✅ Booming orders show market leadersh...
16/09/2022

The Proactive note published today following the publication of our H1 results.

✅ Booming orders show market leadership

✅ Double digit margins

✅ Cash generative - c. £20m (1 Sept)

✅ £80m contracted order book - 1 Sept

Open Orphan (which will be rebranded hVIVO starting 26 October) is a growing specialist contract research organisation (CRO) with a...

09/09/2022
Our caught up with Proactive to discuss our results, featuring operational & financial highlights, the upcoming name...
08/09/2022

Our caught up with Proactive to discuss our results, featuring operational & financial highlights, the upcoming name change from to HVIVO & exciting outlook to H2.

Watch full interview below:
https://www.youtube.com/watch?v=U0ElB9hM2YI

Open Orphan PLC’s CEO, Yamin ‘Mo’ Khan says it was a busy and successful first half with record orders, US laboratory services certification and soaring reve...

Address

Dublin

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm

Website

https://hvivo.com/

Alerts

Be the first to know and let us send you an email when Open Orphan Plc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Building a leading European rare/orphan focused pharma services company

Open Orphan is a rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services and viral laboratory services. It has Europe's only 24-bedroom quarantine clinic with onsite virology lab in Queen Mary's Hospital London. hVIVO supports product development for customers developing antivirals, vaccines and respiratory therapeutics, all particularly relevant and topical in the environment of heightened awareness in 2020. The company also has a leading portfolio of 8 viral challenge study models which are: 2 FLU, 2 RSV, 1 HRV, 1 Asthma, 1 cough and 1 COPD viral challenge models. No other company in the world has such a portfolio, with only two competitors globally having 1 challenge study model each.

Open Orphan comprises of two commercial specialist CRO services businesses (Venn and hVIVO) and is developing an early stage orphan drug genomics data platform business. This platform captures valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls), preclinical, phase I & II clinical trials design and ex*****on. The merger with hVIVO created a European full pharma services company broadening the Company's customer base and with complementary specialist CRO services, widened the range of the Company's service offerings.

Open Orphan (ORPH) is quoted on both the AIM and Euronext Growth markets.